Diagnostics and treatment of prostate cancer after kidney transplantation;Diagnostik und therapie des prostatakarzinoms nach nierentransplantation

Urologe - Ausgabe A

Volumn 45, Issue 1, 2006, Pages 32-37

  Wicht, A ^a   Hamza, A ^a   Loertzer, H ^a   Dietl, M ^a   Heynemann, H ^a   Fornara, P ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Kidney dialysis; Kidney transplantation; Prostate cancer; PSA; Renal failure

Indexed keywords

RAPAMYCIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER THERAPY; EUROPE; HUMAN; IMMUNOMODULATION; INDUSTRIALIZATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERINEUM; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSTATE; PROSTATE CANCER; PUBIC BONE; SURGICAL APPROACH;

ADOLESCENT; ADULT; AGED; COMORBIDITY; FEMALE; GERMANY; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 31544483103     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0961-y     Document Type: Article

References (52)

1. Wolfe RA, Ashby VB, Milford ELet al. (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725-1730
2. Cormier L, Lechevallier E, Barrou Bet al. (2003) Diagnosis and treatment of prostate cancers in renal transplant recipients. Transplantation 75: 237-239
3. Noldus J, Huland H (2003) Treatment of localized prostate cancer. Onkologie 4 [Suppl]: 6-12
4. Noldus J, Palisaar RJ, Huland H (2003) Treatment of prostate cancer - the clinical use of radical prostatectomy. Eur Urol 2(1): 16-22
5. Hafron J, Fogarty JD, Wiesen A, Melman A (2005) Surgery for localized prostate cancer after renal transplantation. BJU Int 95: 319-322
6. Stallone G, Schena A, Infante B et al. (2005) Sirolimus for Kaposi's sarcoma. N Engl J Med 352: 25-31
7. Kliem V, Kolditz M, Behrend M, Ehlerding G, Pichl-mayr R, Koch KM, Brunkhorst R (1997) Risk of renal cell carcinoma after kidney transplantation. Clin Transplant 11: 255-258
8. Birkeland SA, Storm HH, Lamm LU et al. (1995) Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 60: 183-189
9. Dreikorn K, Heicapell R, Heynemann H et al. (2001) Urologic tumors and organ transplantation. Recommendations of the Kidney Transplantation Working Group of the Ongoing Graduate and Continuing Education Committee of the German Society of Urology. Urologe A 40: 493-494
10. Luboldt H, Rubben H (2000) PSA - Früherkennung des Prostatakarzinoms. Urologe 39: 22-26
11. Hammerer P, Lein M (2004) Stellenwert der PSA-Bestimmung zur Früherkennung des Prostatakarzinoms. Dtsch Arztebl 24: 1892-1893
12. Schloerb PR (1997) Prostate cancer transmitted in an orthotopic heart transplant. JAMA 277: 1355
13. van der Poel HG, Hanrahan C, Zhong H, Simsons JW (2003) Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 30: 380-386
14. Ghosch PM, Malik SN, Bedolla RG et al. (2005) Signal transduction pathways in androgen-dependent and - independent prostate cancer cell proliferation. Endocr Relat Cancer 12: 119-134
15. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray BB, Hidalgo M (2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141-6145
16. Djavan B, Shariat S, Ghawidel K et al. (1999) Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? Urology 53: 1169-1174
17. Brunn L, Bjork T, Lilja H, Becker C, Gustafsson O, Christensson A (2003) Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. Nephrol Dial Transplant 18: 598-603
18. Monath JR, Burkart JM, Freedman BI, Pittaway DE, Russell GB, Assimos DG (1993) Effects of hemodialysis on prostate-specific antigen. Urology 42: 398-400
19. Kabalin JN, Hornberger JC (1991) Prostate-specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology 37: 308-310
20. Fornara P, Fischer K, Luboldt HJ, Doehn C, Semjonow A (2004) Einfluss von Präanalytik und Analytik auf die Aussagekraft des prostataspezifischen Antigens. Dtsch Arztebl 25: 1820-1823
21. Fischer K, Fornara P (2002) "Analysegeräte". In: Fornara P, Semjonow A (Hrsg) "PSA: Der Weg zum Befund". Zuckschwerdt, München
22. Sumura M, Yokogi H, Beppu M, Honda H (2003) Diagnostic value of serum prostate-specific antigen in hemodialysis patients. Int J Urol 10: 247-250
23. Tzanakis I, Kazoulis S, Girousis N et al. (2002) Prostate-specific antigen in hemodialysis patients and the influence of dialysis in its levels. Nephron 90: 230-233
24. Wolff JM, Ting O, Borchers H, Rohde D, Jakse G (2000) Serum levels of prostate specific antigen in men on hemodialysis. Anticancer Res 20: 5191-5193
25. Passadakis P, Ersoy F, Tam P et al. (2004) Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients. Adv Perit Dial 20: 203-208
26. Harper L, McIntyre CW, MacDougall IC, Meyer P, Raine AE, Baker LR (1995) Prostate-specific antigen levels in patients receiving long-term dialysis. Br J Urol 76: 482-483
27. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, Ballesta AM (1990) Tumor markers in patients with chronic renal failure. Int J Biol Markers 5: 85-88
28. Douville P, Tiberi M (1998) Effect of terminal renal failure on the ratio of free to total prostate-specific antigen. Tumour Biol 19: 113-117
29. Arik N, Adam B, Akpolat T, Hasil K, Tabak S (1996) Serum tumour markers in renal failure. Int Urol Nephrol. 28: 601-604
30. Danisman A, Kilic S, Kukul E, Yakupoglu G, Guntekin E, Baykara M, Sevuk M (2000) Do renal failure and hemodialysis have any effect on the elimination of free and total prostate-specific antigen? Eur Urol 37: 579-581
31. Lye WC, Tambyah P, Leong SO, Lee EJ (1994) Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial 10: 109-111
32. Morton JJ, Howe SF, Lowell JA, Stratta RJ, Taylor RJ (1995) Influence of end-stage renal disease and renal transplantation on serum prostate-specific antigen. Br J Urol 75: 498-501
33. Sasagawa I, Kubota Y, Hayami S, Adachi M, Nakada T, Miura H, Imai K (1998) Serum levels of total and free prostate specific antigen in men on hemodialysis. J Urol 160: 83-85
34. Sasagawa I, Nakada T, Hashimoto T et al. (1992) Serum prostatic acid phosphatase, gamma-semino-protein and prostatic specific antigen in hemo-dialysis patients. Urol Int 48: 181-183
35. Honda SA, Goldstein AP, Morita T, Sugiyama C, Cody L, Rios CN, Bhagavan NV (1996) Prostate-specific antigen concentrations in serum in acute illnesses. Clin Chem 42: 1785-1788
36. Gillitzer R, Thuroff JW (2002) Relative advantages and disadvantages of radical perineal prostatectomy versus radical retropubic prostatectomy. Crit Rev Oncol Hematol 43: 167-190
37. Guillonneau B, el-Fettouh H, Baumert H, Cathelineau X, Doublet JD, Fromont G, Vallancien G (2003) Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases at Montsouris Institute. J Urol 169: 1261-1266
38. Yiou R, Salomon L, Colombel M, Patard JJ, Chopin D, Abbou CC (1999) Perineal approach to radical prostatectomy in kidney transplant recipients with localized prostate cancer. Urology 53: 822-824
39. Schönberger B, Giessing M, Vogler H, Budde K, Loening S (2002) Relevance and meaning of prostate cancer in kidney transplantation. Transplant Proc 34: 2225-2226
40. Guillonneau B, Vallancien G (2000) Laparoscopic radical prostatectomy: The Montsouris Technique. J Urol 163: 1643-1649
41. Stolzenburg JU, Truss MC, Do M et al. (2003) Evolution of endoscopic extraperitoneal radical prostatectomy (EERPE) - technical improvements and development of a nerve-sparing, potency-preserving approach. World J Urol 21: 147-152
42. Kinahan TJ, McLoughlin MG, Manson AD (1991) Radical prostatectomy for localized prostatic carcinoma in the renal transplant patient. J Urol 146: 104-107
43. Campagnari JC, Ribeiro LA, Mangini M, Campagnari M, Rodrigues PR, D'Imperio M (2002) Localized prostatic cancer in patients submitted to renal transplant. Int Braz J Urol 28: 330-334
44. Secin FP, Carver B, Kattan MW, Eastham JA (2004) Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate. Transplantation 78: 710-712
45. Mouzin M, Bachaud JM, Kamar N et al. (2004) Three-dimensional conformal radiotherapy for localized prostate cancer in kidney transplant recipients. Transplantation 78: 1496-1500
46. Mousses S, Wagner U, Chen Y et al. (2001) Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signalling. Oncogene 20: 6718-6723
47. Multanen MT, Lindell OI (1998) Radical prostatectomy for localized prostatic carcinoma in a renal transplant patient. Scand J Urol Nephrol 32: 221-222
48. Hudson CC, Liu M, Chiang GG et al. (2002) Regulation of hypoxia-inducible factor 1!alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014
49. Kattan MW, Eastham J (2003) Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer. Clin Prostate Cancer 1: 221-226
50. Secin FP, Carver B, Kattan MW, Eastham JA (2004) Current recommendations for delaying renal transplantation after localized prostate cancer treatment: are they still appropriate? Transplantation 78: 710-712
51. Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55: 742-747
52. Penn I (1997) Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 2: 14-17